Get started
Beyond Air, Inc.Beyond Air, Inc.Beyond Air, Inc.

Beyond Air, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

XAIR trade ideas

$xair Covid-19 treatment Hopes First target hit nicely and lets see if we can get some continuation in the days to come. Speculation on social media about the stock is high in anticipation of their technology getting fast tracked for COVID-19 treatment, keep it on your watch-list, had some unusual moves in Fridays after-hours. THESE CHARTS AND STATEMENTS ARE OPINIONS ONLY AND NOT ADVICE, BUT PLEASE BE CAREFUL AND DON'T BE FOOLED BY SHORT TERM RALLIES, USE YOUR OWN BRAIN NOT THAT OF CELEBRITY INVESTORS AND ANALYSTS, THEIR INTERESTS ARE NOT YOURS.
NASDAQ:XAIR
by Bullishcharts
1
Beyond Air Submits COVID19 Device to FDABeyond Air Submits Investigational Device Exemption (IDE) to the United States Food and Drug Administration (FDA) for the Treatment of COVID-19 Patients Recent article by Smateranlysis In a report released today, Suraj Kalia from Oppenheimer maintained a Buy rating on Beyond Air (XAIR), with a price target of $9.00. The company’s shares closed last Monday at $4.41, close to its 52-week low of $3.45. According to TipRanks.com, Kalia is a 4-star analyst with an average return of 1.4% and a 50.4% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Inspire Medical Systems, and Edwards Lifesciences. Beyond Air has an analyst consensus of Moderate Buy, with a price target consensus of $9.00. See tday’s analyst top recommended stocks >> Based on Beyond Air’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $4.4 million. In comparison, last year the company had a net profit of $957.6K. Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of XAIR in relation to earlier this year. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company. It engages in the developing a nitric oxide generator and delivery system that uses nitric oxide generated from ambient air and delivers precise amounts of nitric oxide to the lungs for the potential treatment of respiratory and other diseases.
NASDAQ:XAIRLong
by RedHotStocks
2
Beyond Air Submits Covid-19 device to FDA Beyond Air, Inc. (XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including, serious lung infections and pulmonary hypertension, and gaseous NO for the treatment of solid tumors, today announced submission of an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) for use of its LungFitTM BRO system in the treatment of COVID-19 patients. Typically, the FDA responds within 30 days of an IDE submission. “There is a mounting body of evidence that inhaled NO, including NO generated and delivered by our LungFitTM BRO system, is safe and well-tolerated in animals and in human subjects at concentrations of 150 ppm and higher. In vitro evidence1 points to inhibition of viral replication in a variety of viruses, including coronaviruses, as well as anti-inflammatory properties of nitric oxide,” said Steve Lisi, Chairman and Chief Executive Officer of Beyond Air. “We believe that our LungFitTM BRO system may, given the three completed pilot clinical studies in bronchiolitis, be a significant tool in the battle against this coronavirus that has reached global pandemic status. In response to the unprecedented nature of the COVID-19 situation, Beyond Air is taking all necessary steps to make this potential solution available as quickly as possible to ensure that clinicians have access to NO therapy as a treatment option.” “Nitric oxide therapy at high concentrations is an innovative and potentially ground breaking treatment option against COVID-19. The LungFitTM BRO system is a practical and effective mode of delivery of nitric oxide for both patients and medical teams,” added Andrew Colin, M.D., Batchelor Family Professor of Cystic Fibrosis and Pediatric Pulmonology Director, Division of Pediatric Pulmonology Miller School of Medicine University of Miami. “Combatting this pandemic is of crucial importance and having the LungFitTM BRO system tested and available as expeditiously as possible should be a priority for all parties.”
NASDAQ:XAIR
by Bullishcharts
Beyond Air Breaking Out $XAIRBeyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company. It engages in the developing a nitric oxide generator and delivery system that uses nitric oxide generated from ambient air and delivers precise amounts of nitric oxide to the lungs for the potential treatment of respiratory and other diseases. The company develops LungFit platform system, a generator and delivery system that produces nitric oxide from ambient air, eliminating the need for expensive and cumbersome cylinders. Beyond Air was founded in 2011 and is headquartered in Garden City, NY.
NASDAQ:XAIRLong
by RedHotStocks